Vaccines (Nov 2023)

Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in Rabbits

  • Selina Khan,
  • Sonia Marquez-Martinez,
  • Tim Erkens,
  • Adriaan de Wilde,
  • Lea M. M. Costes,
  • Petra Vinken,
  • Sandra De Jonghe,
  • Wendy Roosen,
  • Chiara Talia,
  • Ronnie Chamanza,
  • Jan Serroyen,
  • Jeroen Tolboom,
  • Roland C. Zahn,
  • Frank Wegmann

DOI
https://doi.org/10.3390/vaccines11121792
Journal volume & issue
Vol. 11, no. 12
p. 1792

Abstract

Read online

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a very rare but serious adverse reaction that can occur after Ad26.COV2.S vaccination in humans, leading to thrombosis at unusual anatomic sites. One hypothesis is that accidental intravenous (IV) administration of Ad26.COV2.S or drainage of the vaccine from the muscle into the circulatory system may result in interaction of the vaccine with blood factors associated with platelet activation, leading to VITT. Here, we demonstrate that, similar to intramuscular (IM) administration of Ad26.COV2.S in rabbits, IV dosing was well tolerated, with no significant differences between dosing routes for the assessed hematologic, coagulation time, innate immune, or clinical chemistry parameters and no histopathologic indication of thrombotic events. For both routes, all other non-adverse findings observed were consistent with a normal vaccine response and comparable to those observed for unrelated or other Ad26-based control vaccines. However, Ad26.COV2.S induced significantly higher levels of C-reactive protein on day 1 after IM vaccination compared with an Ad26-based control vaccine encoding a different transgene, suggesting an inflammatory effect of the vaccine-encoded spike protein. Although based on a limited number of animals, these data indicate that an accidental IV injection of Ad26.COV2.S may not represent an increased risk for VITT.

Keywords